MCID: HYP263
MIFTS: 44

Hypersomnia

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Hypersomnia

MalaCards integrated aliases for Hypersomnia:

Name: Hypersomnia 54 73

Classifications:



External Ids:

UMLS 73 C0917799

Summaries for Hypersomnia

NINDS : 54 Hypersomnia is characterized by recurrent episodes of excessive daytime sleepiness or prolonged nighttime sleep. Different from feeling tired due to lack of or interrupted sleep at night, persons with hypersomnia are compelled to nap repeatedly during the day, often at inappropriate times such as at work, during a meal, or in conversation. These daytime naps usually provide no relief from symptoms. Patients often have difficulty waking from a long sleep, and may feel disoriented. Other symptoms may include anxiety, increased irritation, decreased energy, restlessness, slow thinking, slow speech, loss of appetite, hallucinations, and memory difficulty. Some patients lose the ability to function in family, social, occupational, or other settings. Hypersomnia may be caused by another sleep disorder (such as narcolepsy or sleep apnea), dysfunction of the autonomic nervous system, or drug or alcohol abuse. In some cases it results from a physical problem, such as a tumor, head trauma, or injury to the central nervous system. Certain medications, or medicine withdrawal, may also cause hypersomnia. Medical conditions including multiple sclerosis, depression, encephalitis, epilepsy, or obesity may contribute to the disorder. Some people appear to have a genetic predisposition to hypersomnia; in others, there is no known cause. Typically, hypersomnia is first recognized in adolescence or young adulthood.

MalaCards based summary : Hypersomnia is related to idiopathic hypersomnia and recurrent hypersomnia, and has symptoms including excessive daytime somnolence, sleep disturbances and snoring. An important gene associated with Hypersomnia is HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1), and among its related pathways/superpathways are Phagosome and Cell adhesion molecules (CAMs). The drugs Armodafinil and Modafinil have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and heart.

Wikipedia : 76 Hypersomnia, or hypersomnolence, is a neurological disorder of excessive time spent sleeping or... more...

Related Diseases for Hypersomnia

Diseases in the Hypersomnia family:

Recurrent Hypersomnia

Diseases related to Hypersomnia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 105)
# Related Disease Score Top Affiliating Genes
1 idiopathic hypersomnia 34.1 HCRT HLA-DQB1
2 recurrent hypersomnia 33.7 HCRT HLA-DQB1
3 kleine-levin hibernation syndrome 32.6 HCRT HLA-DQB1
4 narcolepsy 30.1 CHKB CPT1B HCRT HLA-DQB1 HLA-DRB1
5 neuromyelitis optica 29.9 HCRT HLA-DRB1
6 acute disseminated encephalomyelitis 29.8 HCRT HLA-DQB1 HLA-DRB1
7 whipple disease 29.8 HLA-DQB1 HLA-DRB1
8 idiopathic hypersomnia without long sleep time 12.3
9 idiopathic hypersomnia with long sleep time 12.2
10 dystonia, dopa-responsive, due to sepiapterin reductase deficiency 11.4
11 myotonic dystrophy 2 11.1
12 atypical depressive disorder 11.1
13 sleep apnea 10.4
14 depression 10.4
15 myotonic dystrophy 10.3
16 myotonia atrophica 10.2
17 bipolar disorder 10.1
18 brain injury 10.1
19 traumatic brain injury 10.1
20 prader-willi syndrome 10.1
21 major depressive disorder 10.1
22 mood disorder 10.1
23 limbic encephalitis with lgi1 antibodies 10.1 HLA-DQB1 HLA-DRB1
24 autoimmune polyglandular syndrome type 3 10.1 HLA-DQB1 HLA-DRB1
25 metal allergy 10.1 HLA-DQB1 HLA-DRB1
26 lichen planopilaris 10.1 HLA-DQB1 HLA-DRB1
27 type ii mixed cryoglobulinemia 10.1 HLA-DQB1 HLA-DRB1
28 beryllium disease 10.1 HLA-DQB1 HLA-DRB1
29 recurrent respiratory papillomatosis 10.1 HLA-DQB1 HLA-DRB1
30 chronic beryllium disease 10.1 HLA-DQB1 HLA-DRB1
31 lichen sclerosus 10.1 HLA-DQB1 HLA-DRB1
32 pityriasis rosea 10.1 HLA-DQB1 HLA-DRB1
33 pediatric multiple sclerosis 10.1 HLA-DQB1 HLA-DRB1
34 microscopic colitis 10.1 HLA-DQB1 HLA-DRB1
35 osteonecrosis of the jaw 10.1 HLA-DQB1 HLA-DRB1
36 idiopathic bronchiectasis 10.1 HLA-DQB1 HLA-DRB1
37 peanut allergy 10.1 HLA-DQB1 HLA-DRB1
38 oligoarticular juvenile idiopathic arthritis 10.1 HLA-DQB1 HLA-DRB1
39 endometritis 10.0 CHKB HLA-DQB1
40 glaucomatocyclitic crisis 10.0 HLA-DQB1 HLA-DRB1
41 geographic tongue 10.0 HLA-DQB1 HLA-DRB1
42 panuveitis 10.0 HLA-DQB1 HLA-DRB1
43 apnea, obstructive sleep 10.0
44 encephalitis 10.0
45 encephalopathy 10.0
46 ocular cicatricial pemphigoid 10.0 HLA-DQB1 HLA-DRB1
47 focal epithelial hyperplasia 10.0 HLA-DQB1 HLA-DRB1
48 paraneoplastic pemphigus 10.0 HLA-DQB1 HLA-DRB1
49 vogt-koyanagi-harada disease 10.0 HLA-DQB1 HLA-DRB1
50 rubella 10.0 HLA-DQB1 HLA-DRB1

Graphical network of the top 20 diseases related to Hypersomnia:



Diseases related to Hypersomnia

Symptoms & Phenotypes for Hypersomnia

UMLS symptoms related to Hypersomnia:


excessive daytime somnolence, sleep disturbances, snoring, sleeplessness, insomnia with sleep apnea, unspecified, hypersomnia with sleep apnea, unspecified, disruption of 24 hour sleep wake cycle, unspecified, [d]sleep disturbances (& [hypersomnia] or [insomnia])

Drugs & Therapeutics for Hypersomnia

Drugs for Hypersomnia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 170)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Armodafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 112111-43-0
2
Modafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 68693-11-8 4236
3
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
4
Citalopram Approved Phase 4,Not Applicable 59729-33-8 2771
5
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
6
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
7
Sertraline Approved Phase 4 79617-96-2 68617
8
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
9
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9 26757 5195
10
Imidacloprid Vet_approved Phase 4 105827-78-9 86418
11 Wakefulness-Promoting Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Central Nervous System Stimulants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
16 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2
17 Serotonin Agents Phase 4,Phase 3,Phase 2,Not Applicable
18 Cholinergic Agents Phase 4,Not Applicable
19 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Serotonin Uptake Inhibitors Phase 4,Not Applicable
21 Dopamine Uptake Inhibitors Phase 4,Phase 2,Phase 1,Not Applicable
22 Antiparkinson Agents Phase 4,Phase 2,Not Applicable
23 Antidepressive Agents Phase 4,Phase 3,Phase 2,Not Applicable
24 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Antidepressive Agents, Second-Generation Phase 4,Phase 3,Not Applicable
26 Parasympatholytics Phase 4,Not Applicable
27 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Not Applicable
28 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
29 Autonomic Agents Phase 4,Phase 2,Phase 1,Not Applicable
30 Muscarinic Antagonists Phase 4,Not Applicable
31 Cholinergic Antagonists Phase 4,Not Applicable
32 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
33 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 3,Phase 1,Phase 2
34 Vaccines Phase 4,Phase 3,Phase 1,Phase 2
35 Dopamine agonists Phase 4,Phase 2
36 Sympathomimetics Phase 4,Phase 2,Phase 1
37 Monoamine Oxidase Inhibitors Phase 4
38 Cardiotonic Agents Phase 4
39 Protective Agents Phase 4,Phase 1,Phase 2
40 Neuroprotective Agents Phase 4,Phase 2
41 Anesthetics Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1
42
Serotonin Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 50-67-9 5202
43
Morphine Approved, Investigational Phase 3 57-27-2 5288826
44
Caffeine Approved Phase 2, Phase 3,Not Applicable 58-08-2 2519
45
Histamine Approved, Investigational Phase 3,Phase 2 51-45-6, 75614-87-8 774
46
Norepinephrine Approved Phase 3 51-41-2 439260
47 Ixekizumab Approved, Investigational Phase 3,Phase 2 1143503-69-8
48
Lithium carbonate Approved Phase 3 554-13-2
49
leucovorin Approved Phase 3 58-05-9 6006 143
50
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941

Interventional clinical trials:

(show top 50) (show all 177)
# Name Status NCT ID Phase Drugs
1 Efficacy and Tolerability of Armodafinil in Adults With Excessive Sleepiness Associated With Shift Work Disorder Completed NCT01080807 Phase 4 Armodafinil;Matching Placebo
2 Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression Completed NCT00518986 Phase 4 armodafinil;placebo
3 Study to Evaluate Armodafinil Treatment in Improving Prefrontal Cortical Activation and Working Memory Performance Completed NCT00711516 Phase 4 Armodafinil;Placebo
4 Provigil in Conjunction With SSRIs for the Treatment of Mild or Moderate Depression With Attendant Symptoms of Sleepiness and Fatigue. Completed NCT00208715 Phase 4 Provigil
5 Neuroimaging Study of Bupropion Treatment in Patients With Major Depressive Disorder Completed NCT01541475 Phase 4 Bupropion, Escitalopram;Escitalopram
6 An Eight Week, Double-Blind Efficacy Study of Armodafinil Augmentation to Alleviate Fibromyalgia Fatigue Completed NCT00678691 Phase 4 armodafinil;placebo
7 Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Preterm Compared to Term Infants. Completed NCT01193335 Phase 4
8 Predictors of Antidepressant Response Completed NCT02178696 Phase 4 Celexa or other antidepressant as clinically indicated
9 Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists Completed NCT00443872 Phase 4 orally disintegrating selegiline (Zelapar)
10 A Trial Evaluating a 7-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants. Completed NCT01250756 Phase 4
11 MYnd Analytics Directed Therapy in Depression Recruiting NCT03328052 Phase 4
12 Palatal Implants in Combination With Continuous Positive Airway Pressure to Treat Obstructive Sleep Apnea Terminated NCT00730041 Phase 4
13 Palliative Morphine With or Without Concurrent Modafinil Unknown status NCT01766323 Phase 3 Modafinil;Placebo
14 Study of the Effect of Armodafinil Treatment in Healthy Subjects With Excessive Sleepiness Associated With Jet Lag Disorder Completed NCT00758498 Phase 3 armodafinil;armodafinil;placebo
15 Safety/Efficacy Study With Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Chronic SWSD Completed NCT00080288 Phase 3 Armodafinil 150 mg/day;Placebo
16 Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy Completed NCT00107796 Phase 3 Modafinil
17 PROVIGIL® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome Completed NCT00107848 Phase 3 Modafinil
18 Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome Completed NCT00107809 Phase 3 Modafinil
19 Safety and Efficacy Study of Armodafinil (CEP-10953) in the Treatment of Excessive Sleepiness Associated With Narcolepsy Completed NCT00078377 Phase 3 Armodafinil;Armodafinil;Placebo
20 "Six-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA" Completed NCT02348619 Phase 3 JZP-110
21 "Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA" Completed NCT02348606 Phase 3 JZP-110
22 "Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy" Completed NCT02348593 Phase 3 JZP-110
23 Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea (OSA/H) Syndrome Completed NCT00079677 Phase 3 Armodafinil 150 mg/day;Placebo
24 Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome(OSAHS) Completed NCT00078325 Phase 3 Armodafinil 250 mg/day;Armodafinil 150 mg/day;Placebo
25 Assess the Safety and Effectiveness of PROVIGIL Treatment in Children and Adolescents With Excessive Sleepiness Completed NCT00214968 Phase 3 Modafinil
26 Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness Completed NCT00228553 Phase 3 Armodafinil 100 to 250 mg/day
27 Study to Assess Patient Reported Outcomes With Armodafinil Treatment for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome Completed NCT00228566 Phase 3 Armodafinil
28 "A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA" Completed NCT02348632 Phase 3 JZP-110
29 Armodafinil (CEP-10953) for Treatment of Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder Completed NCT00078312 Phase 3 CEP-10953 (Armodafinil)
30 Caffeine for Excessive Daytime Somnolence in Parkinson's Disease Completed NCT00459420 Phase 2, Phase 3 Caffeine 100-200 mg BID;placebo
31 A Trial of Negative Ion Generation Versus Light-Emitting Diode Phototherapy for Seasonal Affective Disorder (SAD) Completed NCT00809523 Phase 2, Phase 3
32 Efficacy and Safety of DHEA for Myotonic Dystrophy Completed NCT00167609 Phase 2, Phase 3 dehydroepiandrosterone 100 and 400 mg
33 Study of the Efficacy and Multiple-Dose Plasma Concentration-Time Profiles of Armodafinil and PROVIGIL Completed NCT00236080 Phase 3 PROVIGIL 200 mg;Armodafinil 250 mg;Armodafinil 200 mg;Armodafinil 150 mg;Placebo
34 Obstructive Sleep Apnea (OSA), Sleepiness, and Activity in Diabetes Management Completed NCT00801892 Phase 3
35 Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy. Completed NCT01638403 Phase 3 BF2.649;Vigil;palcebo
36 Study Evaluating 13-valent Pneumococcal Conjugate Vaccine Catch-Up Regimens in Older Infants and Children Completed NCT00452452 Phase 3
37 Venlafaxine ER Long-Term Extension Study for Major Depressive Disorder (MDD) Completed NCT01485887 Phase 3 Venlafaxine ER
38 Wyeth Study To Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants Completed NCT00464945 Phase 3
39 Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD) Completed NCT01441440 Phase 3 venlafaxine ER 75 mg/day (fixed dose);venlafaxine ER 75 mg/day to 225 mg/day (flexible dose);Placebo
40 A Study in Japanese Participants With Moderate-to-Severe Psoriasis Completed NCT01624233 Phase 3 80 mg ixekizumab
41 13vPnC Multidose Vial Safety, Tolerability and Immunogenicity Study in Healthy Infants. Completed NCT01964716 Phase 3
42 Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants. Completed NCT00366340 Phase 3
43 Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children. Completed NCT00743652 Phase 3
44 Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants Completed NCT00384059 Phase 3
45 This is an Open-label, Multi-center, Extension Study Designed to Evaluate the Longer Term Safety, Tolerability and Effectiveness of Lurasidone, Flexibly Dosed, Adjunctive to Lithium or Divalproex for the Treatment of Subjects With Bipolar I Disorder Who Have Participated in Study D1050296 Completed NCT01575561 Phase 3 Lurasidone
46 A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment Completed NCT02634801 Phase 3 Fumaric Acid Esters;Methotrexate;Ixekizumab
47 Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex Completed NCT01358357 Phase 3 Lurasidone;Placebo
48 Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants Completed NCT00366899 Phase 3
49 Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 Years Completed NCT00761631 Phase 3
50 Safety & Efficacy Study of Study Drug (Eszopiclone) in Children and Adolescents With Attention-deficit/Hyperactivity Disorder - Associated Insomnia Completed NCT00856973 Phase 3 eszopiclone;eszopiclone;Placebo

Search NIH Clinical Center for Hypersomnia

Genetic Tests for Hypersomnia

Anatomical Context for Hypersomnia

MalaCards organs/tissues related to Hypersomnia:

41
Brain, Testes, Heart, Hypothalamus, Eye, B Cells, Tongue

Publications for Hypersomnia

Articles related to Hypersomnia:

(show top 50) (show all 383)
# Title Authors Year
1
Update on treatment for idiopathic hypersomnia. ( 29250981 )
2018
2
Insomnia and hypersomnia in major depressive episode: Prevalence, sociodemographic characteristics and psychiatric comorbidity in a population-based study. ( 28972930 )
2018
3
A case report of hypersomnia in tetrasomy X improved with medical therapy. ( 29744081 )
2018
4
Prevalence, risk factors, and response to treatment for hypersomnia of central origin in survivors of childhood brain tumors. ( 29116485 )
2018
5
Alternative diagnostic criteria for idiopathic hypersomnia: A 32-hour protocol. ( 29323727 )
2018
6
Idiopathic Hypersomnia Patients Revealed Longer Circadian Period Length in Peripheral Skin Fibroblasts. ( 29930532 )
2018
7
Hypersomnia due to injury of the lower ventral ascending reticular activating system in a patient with intraventricular hemorrhage. ( 29966809 )
2018
8
Associations Between Neuropsychological, Neurobehavioral and Emotional Functioning and Either Narcolepsy or Idiopathic Hypersomnia in Children and Adolescents. ( 29609710 )
2018
9
Nocturnal sleep architecture in idiopathic hypersomnia: a systematic review and meta-analysis. ( 29680423 )
2018
10
Hypothalamic relapse of a cardiac large B-cell lymphoma presenting with memory loss, confabulation, alexia-agraphia, apathy, hypersomnia, appetite disturbances and diabetes insipidus. ( 30150329 )
2018
11
Modafinil: its discovery, the early European and North American experience in the treatment of narcolepsy and idiopathic hypersomnia, and its subsequent use in other medical conditions. ( 30174215 )
2018
12
Hypersomnia. ( 30228690 )
2018
13
A variant at 9q34.11 is associated with HLA-DQB1*06:02 negative essential hypersomnia. ( 30266950 )
2018
14
Mononucleosis: A Possible Cause of Idiopathic Hypersomnia. ( 30429823 )
2018
15
Hypersomnia as an isolated symptom of neuromyelitis optica. ( 30517996 )
2018
16
A Case of Recurrent Hypersomnia With Autonomic Dysfunction. ( 28633719 )
2017
17
[18F]Fludeoxyglucose-Positron Emission Tomography Evidence for Cerebral Hypermetabolism in the Awake State in Narcolepsy and Idiopathic Hypersomnia. ( 28775709 )
2017
18
Hypersomnia: Evaluation, Treatment, and Social and Economic Aspects. ( 28159097 )
2017
19
Hypersomnolence, Hypersomnia, and Mood Disorders. ( 28243864 )
2017
20
Brain MRI findings in patients with idiopathic hypersomnia. ( 28376374 )
2017
21
Recurrent Hypersomnia and Autonomic Dysregulation in Posttraumatic Stress Disorder. ( 29117891 )
2017
22
Hypersomnia hiding a bipolar disorder. ( 28687972 )
2017
23
Test-Retest Reliability of Two Consecutive Mean Sleep Latency Tests in Patients with Hypersomnia. ( 29249902 )
2017
24
Efficacy, Safety, and Tolerability of Armodafinil Therapy for Hypersomnia Associated with Dementia with Lewy Bodies: A Pilot Study. ( 28448998 )
2017
25
Hypersomnia in Neurodegenerative Diseases. ( 28778241 )
2017
26
Life-time history of insomnia and hypersomnia symptoms as correlates of alcohol, cocaine and heroin use and relapse among adults seeking substance use treatment in the United States from 1991 to 1994. ( 28127809 )
2017
27
Val158Met polymorphism in the COMT gene is associated with hypersomnia and mental health-related quality of life in a Colombian sample. ( 28235603 )
2017
28
Neurobiological Basis of Hypersomnia. ( 28778226 )
2017
29
Narcolepsy type 1 and hypersomnia associated with a psychiatric disorder show different slow wave activity dynamics. ( 28691719 )
2017
30
Usefulness of brain SPECT imaging in the study of recurrent hypersomnia: Kleine-Levin syndrome. ( 28869046 )
2017
31
Narcolepsy and hypersomnia in Norwegian children and young adults following the influenza A(H1N1) 2009 pandemic. ( 28302408 )
2017
32
A case of hypersomnia due to bilateral thalamic stroke. ( 29026583 )
2017
33
Hypersomnia: an overlooked, but not overestimated, sleep disturbance in bipolar disorder. ( 28235881 )
2017
34
Depression and Hypersomnia: A Complex Association. ( 28778237 )
2017
35
Idiopathic Hypersomnia. ( 28778232 )
2017
36
Case Report of a Patient With Idiopathic Hypersomnia and a Family History of Malignant Hyperthermia Undergoing General Anesthesia: An Overview of the Anesthetic Considerations. ( 28328583 )
2017
37
Hypersomnia and cognitive impairment in a patient with bipolar disorder - a case report. ( 28866718 )
2017
38
Improving the Comprehensive Care of Patients With Hypersomnia Disorders: A Commentary on "Behavioral Sleep Medicine Services for Hypersomnia Disorders: A Survey Study". ( 27849365 )
2017
39
French consensus. Management of patients with hypersomnia: Which strategy? ( 27865546 )
2017
40
Effectiveness of ramelteon for residual sleep disturbances (hypersomnia) in a patient with premenstrual dysphoric disorder. ( 27868343 )
2017
41
Hypersomnia due to injury of the ventral ascending reticular activating system following cerebellar herniation: A case report. ( 28072702 )
2017
42
Diffusion tensor imaging tractography and MRI perfusion in post traumatic brain injury hypersomnia. ( 28522105 )
2017
43
Altered Regional Cerebral Blood Flow in Idiopathic Hypersomnia. ( 28958044 )
2017
44
Urine Toxicology in Adults Evaluated for a Central Hypersomnia and How the Results Modify the Physician's Diagnosis. ( 27568897 )
2016
45
Benefits and risk of sodium oxybate in idiopathic hypersomnia versus narcolepsy type 1: a chart review. ( 26847972 )
2016
46
Menstruation-Related Hypersomnia Treated with Hormonal Contraception: Case Report and Review of Literature. ( 26932284 )
2016
47
Diurnal and nocturnal cardiovascular variability and heart rate arousal response in idiopathic hypersomnia. ( 27810179 )
2016
48
Injury of the Ascending Reticular Activating System in Patients With Fatigue and Hypersomnia Following Mild Traumatic Brain Injury: Two Case Reports. ( 26871783 )
2016
49
French consensus. Idiopathic hypersomnia: Investigations and follow-up. ( 27838089 )
2016
50
Behavioral Sleep Medicine Services for Hypersomnia Disorders: A Survey Study. ( 26788889 )
2016

Variations for Hypersomnia

Expression for Hypersomnia

Search GEO for disease gene expression data for Hypersomnia.

Pathways for Hypersomnia

GO Terms for Hypersomnia

Cellular components related to Hypersomnia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 trans-Golgi network membrane GO:0032588 9.4 HLA-DQB1 HLA-DRB1
2 endocytic vesicle membrane GO:0030666 9.37 HLA-DQB1 HLA-DRB1
3 ER to Golgi transport vesicle membrane GO:0012507 9.32 HLA-DQB1 HLA-DRB1
4 transport vesicle membrane GO:0030658 9.26 HLA-DQB1 HLA-DRB1
5 clathrin-coated endocytic vesicle membrane GO:0030669 9.16 HLA-DQB1 HLA-DRB1
6 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 8.96 HLA-DQB1 HLA-DRB1
7 MHC class II protein complex GO:0042613 8.62 HLA-DQB1 HLA-DRB1

Biological processes related to Hypersomnia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 T cell receptor signaling pathway GO:0050852 9.4 HLA-DQB1 HLA-DRB1
2 antigen processing and presentation of exogenous peptide antigen via MHC class II GO:0019886 9.37 HLA-DQB1 HLA-DRB1
3 interferon-gamma-mediated signaling pathway GO:0060333 9.32 HLA-DQB1 HLA-DRB1
4 antigen processing and presentation GO:0019882 9.26 HLA-DQB1 HLA-DRB1
5 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.16 HLA-DQB1 HLA-DRB1
6 humoral immune response mediated by circulating immunoglobulin GO:0002455 8.96 HLA-DQB1 HLA-DRB1
7 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 8.62 HLA-DQB1 HLA-DRB1

Molecular functions related to Hypersomnia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide antigen binding GO:0042605 8.96 HLA-DQB1 HLA-DRB1
2 MHC class II receptor activity GO:0032395 8.62 HLA-DQB1 HLA-DRB1

Sources for Hypersomnia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....